These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22174290)

  • 1. A kinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs.
    Pal R; Berlow N
    Pac Symp Biocomput; 2012; ():351-62. PubMed ID: 22174290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
    Perego P; Cossa G; Zuco V; Zunino F
    Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.
    Isaac M; Siu A; Jongstra J
    Drug Resist Updat; 2011; 14(4-5):203-11. PubMed ID: 21601509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW
    Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinases as targets for cancer treatment.
    Giamas G; Stebbing J; Vorgias CE; Knippschild U
    Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
    Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
    Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).
    Ibrahim N; Yu Y; Walsh WR; Yang JL
    Oncol Rep; 2012 May; 27(5):1303-11. PubMed ID: 22323095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
    Broxterman HJ; Georgopapadakou NH
    Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cancer with small-molecular-weight kinase inhibitors.
    Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
    Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.
    Rosetti M; Zoli W; Tesei A; Ulivi P; Fabbri F; Vannini I; Brigliadori G; Granato AM; Amadori D; Silvestrini R
    J Cell Physiol; 2007 Sep; 212(3):710-6. PubMed ID: 17458894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biological framework: translational research from bench to clinic.
    Yarden Y
    Oncologist; 2010; 15 Suppl 5():1-7. PubMed ID: 21138950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
    Bagrodia S; Smeal T; Abraham RT
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):819-31. PubMed ID: 22883054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new approach for prediction of tumor sensitivity to targeted drugs based on functional data.
    Berlow N; Davis LE; Cantor EL; Séguin B; Keller C; Pal R
    BMC Bioinformatics; 2013 Jul; 14():239. PubMed ID: 23890326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.